Aug. 14 at 7:29 PM
$EPRX “The expansion into the placebo-controlled, Phase 2b portion of the RESOLVE trial represents a key clinical milestone for #Eupraxia, as we seek to advance EP-104GI for the treatment of #eosinophilicesophagitis,” said Dr. James A. Helliwell, Director and Chief Executive Officer of Eupraxia. “Recent data updates support the potential of EP-104GI as a durable treatment option. In the most recent data update, all three patients demonstrated a sustained or improved treatment outcome after nine months of therapy. We look forward to announcing more results from the Phase 1b/2a portion of the RESOLVE trial in October. As we continue to survey the treatment landscape for #EoE, we are increasingly confident in the potential of EP-104GI to fundamentally transform the therapeutic management of EoE. We are off to a strong start with respect to enrollment in the Phase 2b study and we are looking forward to reporting topline results.”
Eupraxia Pharmaceuticals
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-second-quarter-202500490.html
